Clinical Trials for Cancer Type: Breast

28 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
ALLIANCE-A011502 (CIRB) A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial Open
ALLIANCE-A221505 (CIRB) Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction Open
ECOG-EAY131 (CIRB) Molecular Analysis for Therapy Choice (MATCH) Open
NRG-BR002 (CIRB) A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer Open
NSABP-B-51 (CIRB) A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Open
SWOG-S1207 (CIRB) Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer Open
SWOG-S1418 (CIRB) A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy Open
SWOG-S1609 (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
UCI-10-24 ATHENA Breast Health Network Open
UCI-14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment Open
UCI-14-49 Mapping Breast Cancer Survivorship and the Survivor Institutional Interface Open
UCI-14-62 Breast Tumor Oxygenation During Exercise Open
UCI-14-67 A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Open
UCI-14-81 Mi Salud, Mi Vida: A Self-Discovery Tool for Latina Breast Cancer Survivors Open
UCI-14-86 Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System Open
UCI-15-83 Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting Open
UCI-16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) Open
UCI-16-02 Breast and Cervical Cancer Survivorship in Zambia: Quality of Life, Social Support, and the Role of HIV/AIDS Open
UCI-16-23 Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized versus Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] Open
UCI-16-96 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Open
UCI-17-05 Understanding Intratumoral Heterogeneity Using Single Cell RNA Sequencing Open
UCI-17-08 Peripheral Hormonal Profile in Women with Breast Lesions Open
UCI-17-22 Epigenetic markers for pesticide exposure and cancer risk Open
UCI-17-43 Blood Collection Protocol for Circulating Tumor Cells, Circulating Cancer Associated Fibroblasts and Tissue Factor in Breast Cancer Patients Open
UCI-17-50 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors Open
UCI-17-90 A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy Open
UCI-18-06 (Quorum) A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment Open
UCI-95-29 Measurement of Breast Tissue Optical Properties Open